Patents Assigned to Dainippon Sumitomo Pharma Co. Ltd.
  • Patent number: 10393757
    Abstract: The present invention provides an agent for determining Alzheimer's disease, comprising an anti-S38AA antibody, a method of determining Alzheimer's disease in a test animal, comprising detecting an S38AA fragment in a sample collected from said animal, and a method of screening for a substance that treats or prevents Alzheimer's disease, comprising contacting a test substance with a cell permitting measurement of production of a S38AA fragment, measuring the production amount of the S38AA fragment in the cell, and comparing the production amount with that of the S38AA fragment in a control cell free of contact with the test substance, and selecting a test substance that down-regulates the production amount of the S38AA fragment as a substance capable of treating or preventing Alzheimer's disease, based on the comparison results.
    Type: Grant
    Filed: December 28, 2011
    Date of Patent: August 27, 2019
    Assignee: DAINIPPON SUMITOMO PHARMA CO., LTD.
    Inventors: Masakazu Hashimoto, Hiroyuki Nakagawa, Mikio Aoki, Lars O. Tjernberg, Bengt Winblad
  • Publication number: 20160168197
    Abstract: A novel compound of the formula (1): wherein X is a tyrosine residue or a methionine residue; Y and Z each are a single bond or the like; R1 is a hydrogen atom or the like; R2 is a hydroxy group or the like; R3 is a hydrogen atom, alkyl group, amino group or the like; R4 is a hydrogen atom, alkyl group, carboxy group or the like; m is 1 or 2; and n is an integer of 0 to 2, with the proviso that when n is 0, R3 is a hydrogen atom or an alkyl group, or a pharmaceutically acceptable salt thereof, and its use in cancer immunotherapy.
    Type: Application
    Filed: February 26, 2016
    Publication date: June 16, 2016
    Applicants: International Institute of Cancer Immunology, Inc., Chugai Seiyaku Kabushiki Kaisha, Dainippon Sumitomo Pharma Co., Ltd.
    Inventors: Toshio NISHIHARA, Masashi Gotoh
  • Publication number: 20150080396
    Abstract: The invention concerns compounds of Formula (I): wherein L1, R1, R2, R3, R4 and X are as defined in the description. The present invention also relates to processes for the preparation of such compounds, pharmaceutical compositions containing them and their use in the treatment of disease, for example cancer.
    Type: Application
    Filed: August 26, 2014
    Publication date: March 19, 2015
    Applicants: DAINIPPON SUMITOMO PHARMA CO., LTD., ASTRAZENECA AB
    Inventors: Nicholas James Bennett, Stephen Thom, Thomas McInally
  • Publication number: 20140350029
    Abstract: Dosage regimens for at least one compound chosen from Iurasidone and pharmaceutically acceptable salts, solvates, clathrates, and stereoisomers thereof are disclosed as are kits and methods for treatment and/or prevention of at least one CNS disorder such as, for example, mixed depression and bipolar disorder, and management of at least one CNS disorder, such as improving quality of life and reversing impairment in learning and memory associated with schizophrenia, comprising administering to a patient a therapeutically or prophylactically effective amount of at least one compound chosen from lurasidone and pharmaceutically acceptable salts, solvates, clathrates, and stereoisomers thereof.
    Type: Application
    Filed: November 30, 2012
    Publication date: November 27, 2014
    Applicant: DAINIPPON SUMITOMO PHARMA CO., LTD.
    Inventor: Antony D Loebel
  • Patent number: 8865896
    Abstract: A method for producing adenine compound (1): wherein m and n are independently an integer of 2 to 5, R1 is C1-6 alkyl group, R2 and R3 are the same or different, and hydrogen atom, or C1-6 alkyl group, or R2 and R3 are combined with an adjacent nitrogen atom to form pyrrolidine, morpholine, piperidine, piperazine, etc., and R4 is C1-3 alkyl group, which comprises a step of reacting compound (2): and compound (3): in the presence of a boron-containing reducing agent.
    Type: Grant
    Filed: January 16, 2009
    Date of Patent: October 21, 2014
    Assignees: Astrazeneca Aktiebolag, Dainippon Sumitomo Pharma Co., Ltd.
    Inventors: Kazuki Hashimoto, Wataru Katoda, Kazuhiko Takahashi, Ayumu Kurimoto
  • Publication number: 20140300025
    Abstract: An oral disintegrating tablet containing (1) D-mannitol, (2) an active ingredient, (3) one or more disintegrating agents selected from the group consisting of crospovidone and carmellose, and (4) one or more lubricants selected from the group consisting of sodium stearyl fumarate and sucrose esters of fatty acids. The oral disintegrating tablet of the present invention has some excellent properties of (1) allowing easy production in a common facility without necessitating a specialized pharmaceutical technique, (2) having an appropriate strength that does not breakdown in the process of distribution, (3) having a fast disintegrating ability in the oral cavity, and (4) also having excellent ingestion feel such as greatly reduced bitterness or gritty feel; therefore, the tablet can be suitably used as a dosage form that is suitable for aged individuals, children, and seriously ill patients.
    Type: Application
    Filed: June 4, 2014
    Publication date: October 9, 2014
    Applicant: DAINIPPON SUMITOMO PHARMA CO., LTD.
    Inventors: Makoto MATSUOKA, Hiroyuki NISHII, Maki Kawamura
  • Publication number: 20140256939
    Abstract: The present invention relates to a novel process for preparing quaternary ammonium salt derivatives.
    Type: Application
    Filed: March 7, 2014
    Publication date: September 11, 2014
    Applicant: Dainippon Sumitomo Pharma Co., Ltd.
    Inventors: Nobuyuki AE, Yuji FUJIWARA
  • Publication number: 20140235651
    Abstract: A preparation for oral administration comprising: a pregelatinized starch comprising N-[4-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]-(2R,3R)-2,3-tetramethylene-butyl]-(1?R,2?S,3?R,4?S)-2,3-bicyclo[2,2,1]-heptanedicarboxylmide hydrochloride (lurasidone) represented by the formula (1) as an active ingredient; a water-soluble excipient; and a water-soluble polymeric binder, the preparation exhibiting an invariant level of elution behavior even when the content of its active ingredient is varied.
    Type: Application
    Filed: February 18, 2014
    Publication date: August 21, 2014
    Applicant: DAINIPPON SUMITOMO PHARMA CO., LTD.
    Inventor: Kazuyuki FUJIHARA
  • Patent number: 8809383
    Abstract: The present invention relates to a novel serotonin reuptake inhibitor which also exhibits 5-HT2C antagonistic action (antidepressive and anxiolytic effects), in particular, 5-HT2C inverse agonistic action comprising Compound (1): or a pharmaceutically acceptable salt thereof wherein R1, R2, R3 and R4 are independently hydrogen or C1-6 alkyl etc.; R5 is C4-7 alkyl or —(CR8R9)r-E; R6, R7, R8 and R9 are independently hydrogen, fluorine or C1-6 alkyl; A is C6-10 aryl or heteroaryl etc.; r is 1, 2, 3 or 4; E is C3-8 cycloalkyl or C6-10 aryl etc.; L is oxygen, sulfur or —NR10—; n is 1, 2 or 3; R10 is hydrogen or C1-6 alkyl etc.; and X is hydrogen or halogen etc.
    Type: Grant
    Filed: September 30, 2013
    Date of Patent: August 19, 2014
    Assignee: Dainippon Sumitomo Pharma Co., Ltd.
    Inventors: Izumi Sasaki, Tomohiro Toyoda, Hidefumi Yoshinaga, Itaru Natsutani, Yoko Takahashi
  • Patent number: 8785406
    Abstract: The present invention provides a lyophilized amrubicin formulation and a process thereof. In the process, the concentration of the aqueous solution before lyophilization is controlled to about 7.5 mg(potency)/mL or more. Thus, the formulation decreases the production of desaccharified compound and is stable to storage for a long period. The formulation is useful as a cancer chemotherapeutic agent.
    Type: Grant
    Filed: May 27, 2009
    Date of Patent: July 22, 2014
    Assignee: Dainippon Sumitomo Pharma Co., Ltd.
    Inventors: Hajimu Hirofuji, Hotaka Hashimoto, Kazunari Tanaka
  • Patent number: 8778970
    Abstract: Provided is a new serotonin-reuptake inhibitor that exhibits affinity for serotonin-1A receptors. Said serotonin-reuptake inhibitor is a compound represented by formula (1) or a pharmacologically acceptable salt thereof. In the formula, R1 represents a hydrogen atom, a 2-hydroxyethyl group, or a 2-methoxyethyl group. R2 represents one of the following bonded to a methylene group which is bonded to a piperidine ring: a chlorine atom bonded in a p-position; a bromine atom bonded in a p-position; a methyl group bonded in a p-position; a chlorine atom bonded in an m-position; or a bromine atom bonded in an m-position. Either Y1 represents a hydrogen atom and Y2 represents a hydrogen atom or a hydroxyl group, or Y1 and Y2 together represent an oxo group. Z represents a group represented by one of the following formulas: formula (3-1-1), formula (3-1-2), formula (3-2-1), formula (3-2-2), formula (3-3-1), formula (3-3-2), formula (3-4-1), or formula (3-4-2).
    Type: Grant
    Filed: August 4, 2010
    Date of Patent: July 15, 2014
    Assignee: Dainippon Sumitomo Pharma Co., Ltd
    Inventors: Tomohiro Toyoda, Tomoaki Nishida, Hidefumi Yoshinaga
  • Patent number: 8778392
    Abstract: An oral disintegrating tablet containing (1) D-mannitol, (2) an active ingredient, (3) one or more disintegrating agents selected from the group consisting of crospovidone and carmellose, and (4) one or more lubricants selected from the group consisting of sodium stearyl fumarate and sucrose esters of fatty acids. The oral disintegrating tablet of the present invention has some excellent properties of (1) allowing easy production in a common facility without necessitating a specialized pharmaceutical technique, (2) having an appropriate strength that does not breakdown in the process of distribution, (3) having a fast disintegrating ability in the oral cavity, and (4) also having excellent ingestion feel such as greatly reduced bitterness or gritty feel; therefore, the tablet can be suitably used as a dosage form that is suitable for aged individuals, children, and seriously ill patients.
    Type: Grant
    Filed: March 12, 2008
    Date of Patent: July 15, 2014
    Assignee: Dainippon Sumitomo Pharma Co., Ltd.
    Inventors: Makoto Matsuoka, Hiroyuki Nishii, Maki Kawamura
  • Patent number: 8765786
    Abstract: A medicament for treating diseases associated with cholinergic properties in the central nervous system (CNS) and/or peripheral nervous system (PNS), diseases associated with smooth muscle contraction, endocrine disorders, neurodegenerative disorders and the like, which comprises a compound of Formula (I), wherein A is CR1E or a nitrogen atom, X—Y—Z is N—CO—NR3AR3B and the like, R1A to R1E are each independently a hydrogen atom and the like, R2A to R2D are each independently a hydrogen atom and the like, R3A and R3B are each independently an optionally-substituted C3-10 cycloalkyl and 15 the like, and n is 1 or 2 or a pharmaceutically acceptable salt thereof, which exhibits potent modulatory-effects on the activity of alpha-7 nicotinic acetylcholine receptor (alpha-7 nAChR).
    Type: Grant
    Filed: December 20, 2013
    Date of Patent: July 1, 2014
    Assignee: Dainippon Sumitomo Pharma Co., Ltd.
    Inventors: Shinya Usui, Hiroki Yamaguchi, Yoko Nakai
  • Patent number: 8765939
    Abstract: The present invention provides compounds of formula (I) wherein R1, R2, R3 and R4 are as defined in the specification, and pharmaceutically acceptable salts thereof, as well as processes for their preparation, pharmaceutical compositions containing them and their use in therapy.
    Type: Grant
    Filed: August 16, 2012
    Date of Patent: July 1, 2014
    Assignees: AstraZeneca AB, Dainippon Sumitomo Pharma Co., Ltd.
    Inventors: Nicholas J. Bennett, Thomas McInally, Tobias Mochel, Stephen Thom, Anna-Karin Tidén
  • Publication number: 20140179670
    Abstract: The present invention provides: an uracil derivative represented by general formula (I) or a physiologically acceptable salt thereof (in the formula, R1 represents a hydrogen atom, a C1-10 alkyl group, a C2-6 alkene group or a 3- to 6-membered saturated or 4- to 6-membered unsaturated aliphatic ring group which may contain 1 to 2 hetero atoms independently selected from the group consisting of N, O and S; R2 represents a hydrogen atom, a halogen atom, a cyano group, —NRcRd, —N?CHN(CH3)2, or an C1-3 alkyl group; Ar1 and Ar2 independently represent a 5- to 6-membered aromatic ring group which may contain 1 to 3 hetero atoms independently selected from the group consisting of N, O and S; and L represents a 6-membered aromatic ring group which may contain 1 to 4 nitrogen atoms, a pyrazole group, a triazole group, or an imidazole group); and a therapeutic agent or prophylactic agent for various inflammatory diseases associated with elastase, comprises the compound or the like as an active ingredient.
    Type: Application
    Filed: July 31, 2012
    Publication date: June 26, 2014
    Applicant: DAINIPPON SUMITOMO PHARMA CO., LTD.
    Inventors: Tomoya Shiro, Masanori Tobe, Katsumi Kubota, Yosuke Takanashi, Tomoaki Nakamura, Toshihiko Sone
  • Patent number: 8742091
    Abstract: Means for transferring efficiently a desired nucleic acid into a cell is provided. The present invention comprises using a complex comprising a collagen or a collagen derivative, and a desired nucleic acid.
    Type: Grant
    Filed: June 20, 2002
    Date of Patent: June 3, 2014
    Assignees: Dainippon Sumitomo Pharma Co., Ltd., Koken Co., Ltd., National Cancer Center
    Inventors: Masaaki Terada, Takahiro Ochiya, Yu Aso, Kimi Honma, Akihiko Sano, Shunji Nagahara
  • Patent number: 8735406
    Abstract: The present invention provides a compound represented by the formula (1) or a pharmaceutically acceptable salt thereof (wherein W represents a hydrogen atom, a halogen atom, or the others; A represents an alkyl group optionally substituted by aryl group or the others, an aryl group, or the others; and one of X and Y represents a di-substituted alkylaminocarbonyl group, or the others, and the other represents a hydrogen atom, an alkyl group, an alkylcarbonyl group, or the others); a medicament or a pharmaceutical composition for treatment or prophylaxis of FAAH-related diseases such as depression, anxiety disorder or pains, comprising the compound or the like as an active ingredient; a use of the compound or the like; and a method for treatment or prophylaxis using the compound or the like.
    Type: Grant
    Filed: September 8, 2010
    Date of Patent: May 27, 2014
    Assignee: Dainippon Sumitomo Pharma Co., Ltd.
    Inventors: Keiji Adachi, Yoko Nakai, Tomoyuki Furuta, Yuki Fujii
  • Patent number: 8735397
    Abstract: The invention relates to a method for treating schizophrenia and/or related diseases comprising administering lurasidone and a mGluR2 ligand to a mammal in need thereof.
    Type: Grant
    Filed: March 28, 2011
    Date of Patent: May 27, 2014
    Assignees: Vanderbilt University, Dainippon Sumitomo Pharma Co., Ltd.
    Inventors: Herbert Y. Meltzer, Masakuni Horiguchi
  • Patent number: 8729085
    Abstract: A preparation for oral administration comprising: a pregelatinized starch comprising N-[4-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]-(2R,3R)-2,3-tetramethylene-butyl]-(1?R,2?S,3?R,4?S)-2,3-bicyclo[2,2,1]-heptanedicarboxyimide hydrochloride (lurasidone) represented by the formula (1) as an active ingredient; a water-soluble excipient; and a water-soluble polymeric binder, the preparation exhibiting an invariant level of elution behavior even when the content of its active ingredient is varied.
    Type: Grant
    Filed: May 26, 2006
    Date of Patent: May 20, 2014
    Assignee: Dainippon Sumitomo Pharma Co., Ltd.
    Inventor: Kazuyuki Fujihara
  • Publication number: 20140135352
    Abstract: The present invention provides a tablet having improved dissolution property, which comprises (+)-3-{1-[3-(trifluoromethoxy)benzyl]piperidin-4-yl}-4-phenyl-3,4-dihydro-2(1H)-quinazolinone or a pharmaceutically acceptable salt thereof as an active component, and a production method thereof. A film-coated tablet obtained by mixing granulated particles obtained by granulating a mixture containing (a) the aforementioned active component, (b) one or more kinds of fillers selected from lactose, D-mannitol, erythritol and crystalline cellulose, (c) a cellulose-based disintegrant and (d) a water-soluble binder with a later powder containing (e) one or more kinds of fillers selected from lactose, D-mannitol and crystalline cellulose and/or (f) a cellulose-based disintegrant, forming the mixture, and applying film coating.
    Type: Application
    Filed: January 22, 2014
    Publication date: May 15, 2014
    Applicant: DAINIPPON SUMITOMO PHARMA CO., LTD.
    Inventors: Makiko YANAGIDA, Hiroyuki NISHII, Masayuki NAKAZONO